

# Filip K Knop

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3590468/publications.pdf>

Version: 2024-02-01

461  
papers

18,344  
citations

13099

68  
h-index

21540

114  
g-index

496  
all docs

496  
docs citations

496  
times ranked

18094  
citing authors

#	ARTICLE	IF	CITATIONS
1	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 59, 2100752.	6.7	31
2	Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 98-108.	3.6	7
3	Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 142-147.	4.4	4
4	Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 923-935.	2.6	6
5	Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1927-1934.	0.7	3
6	Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 221-227.	4.4	5
7	Glucagon Clearance Is Preserved in Type 2 Diabetes. <i>Diabetes</i> , 2022, 71, 73-82.	0.6	6
8	Hemoglobin A1c and Fructosamine Evaluated in Patients with Type 2 Diabetes Receiving Peritoneal Dialysis Using Long-Term Continuous Glucose Monitoring. <i>Nephron</i> , 2022, 146, 146-152.	1.8	4
9	The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. <i>European Journal of Endocrinology</i> , 2022, 186, 207-221.	3.7	3
10	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake. <i>Obesity Surgery</i> , 2022, 32, 1385-1390.	2.1	0
11	FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. <i>Cell Metabolism</i> , 2022, 34, 317-328.e6.	16.2	30
12	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
13	MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00327.	2.4	3
14	THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology. <i>European Journal of Endocrinology</i> , 2022, 186, R93-R111.	3.7	4
15	Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. <i>Diabetes Care</i> , 2022, 45, 1476-1481.	8.6	6
16	Beta-Hydroxybutyrate Suppresses Hepatic Production of the Ghrelin Receptor Antagonist LEAP2. <i>Endocrinology</i> , 2022, 163, .	2.8	10
17	Acute changes in plasma glucose increases left ventricular systolic function in insulin-treated patients with type 2 diabetes and controls. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1123-1131.	4.4	3
18	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. <i>Cell Reports Medicine</i> , 2022, 3, 100582.	6.5	21

#	ARTICLE	IF	CITATIONS
19	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	4.4	5
20	MO408: Hepatic Steatosis in Patients With Type 2 Diabetes and Chronic Kidney Disease. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
21	The Liverâ€Î±-Cell Axis in Health and in Disease. Diabetes, 2022, 71, 1852-1861.	0.6	26
22	Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 2027-2037.	4.4	4
23	The effect of curcumin on hepatic fat content in individuals with obesity. Diabetes, Obesity and Metabolism, 2022, 24, 2192-2202.	4.4	8
24	Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 168-173.	3.6	11
25	Glycemic, maternal and neonatal outcomes in women with type 1 diabetes using continuous glucose monitoring during pregnancy â€ Pump vs multiple daily injections, a secondary analysis of an observational cohort study. Acta Obstetrica Et Gynecologica Scandinavica, 2021, 100, 927-933.	2.8	13
26	Reduced erythrocyte lifespan measured by chromiumâ€51 in patients with typeâ€2 diabetes undergoing longâ€term hemodialysis. Hemodialysis International, 2021, 25, 198-204.	0.9	1
27	The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis. Nephron, 2021, 145, 27-34.	1.8	9
28	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e966-e981.	3.6	22
29	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP</scp> receptor antagonist <scp>GIP</scp> (3â€30) <scp>NH<sub>2</sub></scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	4.4	14
30	Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. Clinical Nutrition, 2021, 40, 1013-1021.	5.0	9
31	Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. American Journal of Clinical Nutrition, 2021, 113, 314-323.	4.7	24
32	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes, Obesity and Metabolism, 2021, 23, 17-35.	4.4	27
33	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. BMJ Open, 2021, 11, e044711.	1.9	3
34	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. Diabetes, 2021, 70, 1347-1356.	0.6	9
35	INPP4B protects from metabolicÂ syndrome and associated disorders. Communications Biology, 2021, 4, 416.	4.4	10
36	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology, 2021, 184, 383-394.	3.7	15

#	ARTICLE	IF	CITATIONS
37	Response to Letter to the Editor from McKee and McGill: "Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring". Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4307-e4308.	3.6	0
38	MO633GLYCAEMIC MARKERS IN PATIENTS WITH TYPE 2 DIABETES UNDERGOING HAEMODIALYSIS EVALUATED BY LONG-TERM CONTINUOUS GLUCOSE MONITORING*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
39	Expression of Cholecystokinin and its Receptors in the Intestinal Tract of Type 2 Diabetes Patients and Healthy Controls. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2164-2170.	3.6	10
40	Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 1666-1671.	4.4	4
41	MO457PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A CASE-CONTROL STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
42	Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo. Diabetic Medicine, 2021, 38, e14592.	2.3	1
43	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs, 2021, 81, 1003-1030.	10.9	27
44	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. European Journal of Endocrinology, 2021, 185, 343-353.	3.7	12
45	Predictors of Improvement in Quality of Life When Treating Hypothyroidism. Journal of Thyroid Research, 2021, 2021, 1-7.	1.3	6
46	Systemic Corticosteroids and the Risk of Venous Thromboembolism in Patients with Severe COPD: A Nationwide Study of 30,473 Outpatients. Biomedicines, 2021, 9, 874.	3.2	4
47	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. European Journal of Endocrinology, 2021, 185, 23-32.	3.7	2
48	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	3.7	21
49	How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 2021, 10, R200-R212.	1.9	17
50	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia, 2021, 64, 2425-2431.	6.3	4
51	Neurotensin secretion after Roux-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. Neurogastroenterology and Motility, 2021, , e14210.	3.0	2
52	Exendin(9-39)NH <sub>2</sub> : Recommendations for clinical use based on a systematic literature review. Diabetes, Obesity and Metabolism, 2021, 23, 2419-2436.	4.4	15
53	Mechanisms in Endocrinology: The physiology of neuronostatin. European Journal of Endocrinology, 2021, 185, R93-R101.	3.7	0
54	Hepatic microbiome in healthy lean and obese humans. JHEP Reports, 2021, 3, 100299.	4.9	15

#	ARTICLE	IF	CITATIONS
55	Treatment of type 2 diabetes in children: what are the specific considerations?. Expert Opinion on Pharmacotherapy, 2021, 22, 1-15.	1.8	5
56	Weight gain on antipsychotics – A perfect storm of complex pathophysiology and psychopharmacology. Acta Psychiatrica Scandinavica, 2021, 144, 521-523.	4.5	3
57	The Accuracy of Hemoglobin A1c and Fructosamine Evaluated by Long-Term Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing Hemodialysis. Blood Purification, 2021, , 1-9.	1.8	0
58	Understanding the place for GLP-1 RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes, Obesity and Metabolism, 2021, 23, 40-52.	4.4	17
59	Study protocol for a multicentre, randomised, parallel group, sham-controlled clinical trial investigating the effect of transcutaneous vagal nerve stimulation on gastrointestinal symptoms in people with diabetes complicated with diabetic autonomic neuropathy: the DAN-VNS Study. BMJ Open, 2021, 11, e038677.	1.9	9
60	Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries. Diabetes Care, 2021, 44, 2767-2774.	8.6	15
61	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine, 2021, 73, 103661.	6.1	31
62	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. ELife, 2021, 10, .	6.0	20
63	Editorial: Proglucagon-Derived Peptides. Frontiers in Endocrinology, 2021, 12, 776871.	3.5	2
64	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study. Cardiovascular Diabetology, 2021, 20, 241.	6.8	17
65	Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials. Journal of Diabetes and Its Complications, 2020, 34, 107446.	2.3	3
66	Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 362-373.	3.6	11
67	Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e564-e574.	3.6	3
68	GIP and the gut-bone axis – Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	2.4	25
69	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	2.4	61
70	Human myotubularin-related protein 9 regulates ER-to-Golgi trafficking and modulates WNT3A secretion. Experimental Cell Research, 2020, 386, 111709.	2.6	2
71	Experience of family function, family involvement, and self-management in adult patients with type 2 diabetes: A thematic analysis. Journal of Advanced Nursing, 2020, 76, 621-631.	3.3	10
72	GIP™s involvement in the pathophysiology of type 2 diabetes. Peptides, 2020, 125, 170178.	2.4	18

#	ARTICLE	IF	CITATIONS
73	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e502-e510.	3.6	12
74	GIP <sup>TM</sup> 's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3 <sup>TM</sup> 30)NH <sub>2</sub> . <i>Bone</i> , 2020, 130, 115079.	2.9	20
75	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. <i>Peptides</i> , 2020, 125, 170174.	2.4	27
76	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. <i>Diabetes</i> , 2020, 69, 2619-2629.	0.6	11
77	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. <i>Nutrients</i> , 2020, 12, 2928.	4.1	2
78	Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. <i>Diabetes Care</i> , 2020, 43, 3050-3060.	8.6	28
79	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. <i>Molecular Metabolism</i> , 2020, 42, 101080.	6.5	66
80	One Year <sup>TM</sup> 's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3213.	2.4	14
81	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2161-2169.	4.4	1
82	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. <i>Diabetes Care</i> , 2020, 43, 2226-2233.	8.6	36
83	Efficacy and Safety of Climepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). <i>Diabetes Care</i> , 2020, 43, 2025-2033.	8.6	22
84	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. <i>Bone</i> , 2020, 140, 115553.	2.9	25
85	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa097.	0.2	12
86	Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study. <i>ESC Heart Failure</i> , 2020, 7, 4189-4197.	3.1	77
87	Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. <i>Trials</i> , 2020, 21, 867.	1.6	6
88	High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016828.	3.7	15
89	Gut Mucosal Gene Expression and Metabolic Changes After Roux-Y Gastric Bypass Surgery. <i>Obesity</i> , 2020, 28, 2163-2174.	3.0	7
90	Pregnancy loss is associated with type 2 diabetes: a nationwide case-control study. <i>Diabetologia</i> , 2020, 63, 1521-1529.	6.3	24

#	ARTICLE	IF	CITATIONS
91	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. <i>Diabetologia</i> , 2020, 63, 1285-1298.	6.3	11
92	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. <i>Alcohol</i> , 2020, 87, 29-37.	1.7	4
93	Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study. <i>Journal of Sports Sciences</i> , 2020, 38, 2080-2091.	2.0	18
94	Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 513.	1.6	10
95	Hypoglycaemia and cardiac arrhythmias in diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882091180.	3.2	25
96	Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1639-1647.	4.4	3
97	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1 $\alpha$ Mutation Carriers. <i>Diabetes</i> , 2020, 69, 1989-2002.	0.6	14
98	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 313-324.	11.4	39
99	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2020, 20, 210.	2.0	47
100	What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1253-1265.	5.0	6
101	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 871-882.	1.8	10
102	L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling. <i>Diabetes</i> , 2020, 69, 614-623.	0.6	54
103	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e725-e738.	3.6	37
104	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 588-596.	8.6	38
105	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. <i>Diabetes</i> , 2020, 69, 1090-1099.	0.6	50
106	Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1348-1356.	4.4	19
107	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. <i>Frontiers in Endocrinology</i> , 2020, 11, 617400.	3.5	25
108	GIP(3-30)NH <sub>2</sub> – a tool for the study of GIP physiology. <i>Current Opinion in Pharmacology</i> , 2020, 55, 31-40.	3.5	8



#	ARTICLE	IF	CITATIONS
109	Myocardial Impairment and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19. JACC: Cardiovascular Imaging, 2020, 13, 2474-2476.	5.3	10
110	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. Endocrine Connections, 2020, 9, 747-754.	1.9	6
111	10-LB: Dasiglucagon Ameliorates Postprandial Hypoglycemia after Roux-en-y Gastric Bypass. Diabetes, 2020, 69, 10-LB.	0.6	4
112	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	3
113	2187-PUB: Identifying Risk Predictors for Gastrointestinal Adverse Events with Once-Weekly Semaglutide. Diabetes, 2020, 69, 2187-PUB.	0.6	0
114	1906-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients with Type 2 Diabetes. Diabetes, 2020, 69, 1906-P.	0.6	0
115	160-OR: Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes. Diabetes, 2020, 69, 160-OR.	0.6	0
116	263-OR: Counterregulatory Responses to Hypoglycemia in Totally Pancreatectomized Patients. Diabetes, 2020, 69, 263-OR.	0.6	0
117	923-P: Improved Glycemic Variability and Control without Increased Risk of Hypoglycemia when Linagliptin Is Added to Glimepiride Therapy in Patients with HNF1A-Diabetes. Diabetes, 2020, 69, .	0.6	0
118	1140-P: Empagliflozin Attenuates Fasting and Postprandial Hyperglycemia in Totally Pancreatectomized Patients: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Diabetes, 2020, 69, .	0.6	2
119	1662-P: Lower Expression of Bile Acid Transporters and Fibroblast Growth Factor 19 in Mucosa Biopsies from the Ileocecal Region in Persons with Type 2 Diabetes Compared with Healthy Controls. Diabetes, 2020, 69, .	0.6	4
120	2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes. Diabetes, 2020, 69, 2160-PUB.	0.6	0
121	1052-P: Investigation of the Extrapankreatic Effects of the DPP-4 Inhibitor Sitagliptin: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial in Totally Pancreatectomized Patients. Diabetes, 2020, 69, .	0.6	3
122	1905-P: Downregulation of HMGC2 Expression in Small Intestinal Mucosa Biopsies after Roux-en-Y Gastric Bypass Surgery: A Possible Contributor to GLP-1 Hypersecretion?. Diabetes, 2020, 69, 1905-P.	0.6	0
123	351-OR: Six-Day Subcutaneous GIP Infusion Increases Glycemic Time-in-Range in Patients with Type 1 Diabetes. Diabetes, 2020, 69, 351-OR.	0.6	1
124	2103-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Protects against Cytokine-Induced Cell Death and Exerts Both Insulinotropic and Glucagonotropic Effects in Human Islets. Diabetes, 2020, 69, .	0.6	0
125	1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial. Diabetes, 2020, 69, 1094-P.	0.6	0
126	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. Endocrine Connections, 2020, 9, 1221-1232.	1.9	2



#	ARTICLE	IF	CITATIONS
127	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00257.	2.5	8
128	Long-term use of inhaled corticosteroids and the risk of type 2 diabetes in COPD. , 2020, , .		0
129	Extrapaneatic glucagon: Present status. <i>Diabetes Research and Clinical Practice</i> , 2019, 147, 19-28.	2.8	9
130	New Avenues in the Regulation of Gallbladder Motilityâ€”Implications for the Use of Glucagon-Like Peptideâ€”Derived Drugs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2463-2472.	3.6	16
131	Nonâ€”alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. <i>Liver International</i> , 2019, 39, 2094-2101.	3.9	43
132	Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6403-6416.	3.6	34
133	Glucagon Receptor Signaling and Glucagon Resistance. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3314.	4.1	113
134	The Liverâ€”Î±-Cell Axis and Type 2 Diabetes. <i>Endocrine Reviews</i> , 2019, 40, 1353-1366.	20.1	110
135	Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. <i>Gastroenterology</i> , 2019, 157, 569-571.	1.3	16
136	O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS. <i>Schizophrenia Bulletin</i> , 2019, 45, S198-S199.	4.3	1
137	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretionâ€”A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4092.	4.1	47
138	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>International Journal of Bipolar Disorders</i> , 2019, 7, 8.	2.2	39
139	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. <i>Diabetologia</i> , 2019, 62, 665-675.	6.3	81
140	Glucose metabolism in patients with psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, e41-e41.	1.5	0
141	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 242.	3.5	5
142	Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. <i>BMJ Open</i> , 2019, 9, e024065.	1.9	4
143	Clinical characteristics and glucoseâ€”lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study. <i>Journal of Diabetes</i> , 2019, 11, 690-694.	1.8	3
144	Plasma proteome profiling discovers novel proteins associated with nonâ€”alcoholic fatty liver disease. <i>Molecular Systems Biology</i> , 2019, 15, e8793.	7.2	176

#	ARTICLE	IF	CITATIONS
145	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. <i>World Journal of Hepatology</i> , 2019, 11, 138-149.	2.0	122
146	Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. <i>Diabetologia</i> , 2019, 62, 1143-1153.	6.3	127
147	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2953-2960.	3.6	41
148	Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. <i>Diabetes Care</i> , 2019, 42, 1095-1103.	8.6	28
149	Glucagon Receptor Signaling and Lipid Metabolism. <i>Frontiers in Physiology</i> , 2019, 10, 413.	2.8	112
150	The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 501-510.	1.8	13
151	OP0011â€¦EFFECT OF LIRAGLUTIDE ON BODY WEIGHT AND PAIN IN THE TREATMENT OF OVERWEIGHT AND KNEE OSTEOARTHRITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. , 2019, , .		0
152	<i>N</i>-acyl taurines are endogenous lipid messengers that improve glucose homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24770-24778.	7.1	25
153	Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1448-1451.	1.5	7
154	FRI-339-Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e544.	3.7	0
155	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 293-302.	4.4	69
156	Management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care is noninferior to management in a specialized outpatient clinic: a randomized, noninferiority trial. <i>Diabetic Medicine</i> , 2019, 36, 854-861.	2.3	10
157	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G462-G472.	3.4	162
158	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. <i>Diabetes</i> , 2019, 68, 906-917.	0.6	118
159	Glucose metabolism in patients with psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 264-271.	1.5	17
160	Patient Assessment of Family Function, Glycemic Control and Quality of Life in Adult Patients With Type 2 Diabetes and Incipient Complications. <i>Canadian Journal of Diabetes</i> , 2019, 43, 193-200.	0.8	15
161	Glucose-metabolic effects of oral and intravenous alcohol administration in men. <i>Endocrine Connections</i> , 2019, 8, 1372-1382.	1.9	7
162	A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?. <i>European Journal of Endocrinology</i> , 2019, 181, C5-C8.	3.7	3

#	ARTICLE	IF	CITATIONS
163	1145-P: Acarbose-Induced Glucagon-Like Peptide-1 Secretion Contributes to the Glucose-Lowering Effect of Acarbose. Diabetes, 2019, 68, 1145-P.	0.6	2
164	1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon. Diabetes, 2019, 68, .	0.6	3
165	1976-P: Physiological Effects of GIP(1-30)NH <sub>2</sub> in Healthy Subjects. Diabetes, 2019, 68, 1976-P.	0.6	1
166	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	10
167	981-P: GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in HNF1A Diabetes. Diabetes, 2019, 68, .	0.6	1
168	1980-P: A Characterization of Postprandial Glucose Metabolism and Incretin Hormone Responses in Patients with Bile Acid Malabsorption. Diabetes, 2019, 68, 1980-P.	0.6	0
169	1186-P: Lean Women with Polycystic Ovary Syndrome and Insulin Resistance Have Normal Incretin Effect, which Is Unaffected by Metformin Therapy. Diabetes, 2019, 68, 1186-P.	0.6	0
170	62-OR: Evidence of Gut-Derived Glucagon in Man. Diabetes, 2019, 68, .	0.6	0
171	63-OR: The Physiological Effects of Extrapankreatic Glucagon in Totally Pancreatectomized Patients Evaluated Using Glucagon Receptor Antagonism. Diabetes, 2019, 68, 63-OR.	0.6	0
172	1721-P: Effect of the TCF7L2 Variant rs7903146 T Allele on the Incretin Effect in Individuals with Normal Glucose Tolerance or Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	0
173	23-OR: The Effect of 14-Day Atorvastatin Treatment on Postprandial Glucose Metabolism in Healthy Malesâ€”A Link to Why Statin Therapy Increases the Risk of Type 2 Diabetes?. Diabetes, 2019, 68, .	0.6	0
174	1982-P: Glucagon-Like Peptide-2 Inhibits Postprandial Gallbladder Emptying in Healthy Male Individualsâ€”A Randomized, Double-Blinded, Placebo-Controlled Study. Diabetes, 2019, 68, 1982-P.	0.6	0
175	Glucoseâ€”lowering effects and mechanisms of the bile acidâ€”sequestering resin sevelamer. Diabetes, Obesity and Metabolism, 2018, 20, 1623-1631.	4.4	21
176	Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolites. Endocrine Connections, 2018, 7, 673-680.	1.9	4
177	EJE PRIZE 2018: A gut feeling about glucagon. European Journal of Endocrinology, 2018, 178, R267-R280.	3.7	38
178	Is glucagonâ€”like peptideâ€”1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2018, 20, 1937-1943.	4.4	3
179	FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. Molecular Metabolism, 2018, 11, 96-103.	6.5	62
180	Ghrelin secretion in humans â€”a role for the vagus nerve?. Neurogastroenterology and Motility, 2018, 30, e13295.	3.0	14

#	ARTICLE	IF	CITATIONS
181	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 288-294.	3.6	64
182	Cardiovascular biomarkers in clinical studies of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1350-1360.	4.4	17
183	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. <i>Peptides</i> , 2018, 100, 173-181.	2.4	56
184	Evidence of a liver- $\alpha$ cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. <i>Diabetologia</i> , 2018, 61, 671-680.	6.3	76
185	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. <i>Mayo Clinic Proceedings</i> , 2018, 93, 217-239.	3.0	94
186	Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylinins do not play a significant role in body weight regulation and glycemic control. <i>Peptides</i> , 2018, 101, 32-43.	2.4	15
187	Glucagon-like peptide 1 in health and disease. <i>Nature Reviews Endocrinology</i> , 2018, 14, 390-403.	9.6	304
188	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. <i>Diabetes Care</i> , 2018, 41, 1260-1267.	8.6	13
189	GIP(3-30)NH <sub>2</sub> is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. <i>Diabetologia</i> , 2018, 61, 413-423.	6.3	66
190	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 508-519.	4.4	39
191	Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G91-G96.	3.4	61
192	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. <i>Diabetologia</i> , 2018, 61, 284-294.	6.3	107
193	The bile acid-sequestering resin sevelamer eliminates the acute <sc>GLP</sc>-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 362-369.	4.4	33
194	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. <i>Frontiers in Endocrinology</i> , 2018, 9, 649.	3.5	65
195	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1429-1432.	1.5	17
196	Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes. <i>Nutrition and Diabetes</i> , 2018, 8, 2.	3.2	10
197	Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , 2018, 8, e022517.	1.9	6
198	Response to Letter to the Editor: "Hemodynamic Effects of Glucagon: A Literature Review". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4480-4481.	3.6	0

#	ARTICLE	IF	CITATIONS
199	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 530-536.	1.3	22
200	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 1161-1167.	5.0	9
201	Recovery of gut microbiota of healthy adults following antibiotic exposure. <i>Nature Microbiology</i> , 2018, 3, 1255-1265.	13.3	483
202	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. <i>BMC Endocrine Disorders</i> , 2018, 18, 60.	2.2	4
203	Adaptive changes in pancreas post Roux- $\epsilon$ gastric bypass induced weight loss. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3025.	4.0	15
204	Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2042-2049.	3.6	18
205	SP426HYPOGLYCAEMIC EPISODES EVALUATED BY CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES AND DIALYSIS-DEPENDENT END-STAGE RENAL DISEASE RANDOMISED TO 12-WEEK LIRAGLUTIDE OR PLACEBO TREATMENT. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i492-i492.	0.7	0
206	Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , 2018, 8, e021861.	1.9	3
207	Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. <i>Diabetes Care</i> , 2018, 41, e133-e135.	8.6	16
208	Hemodynamic Effects of Glucagon: A Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1804-1812.	3.6	43
209	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. <i>Physiological Reports</i> , 2018, 6, e13686.	1.7	1
210	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 603-612.	2.5	12
211	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2557-2564.	4.4	28
212	Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. <i>Frontiers in Psychiatry</i> , 2018, 9, 781.	2.6	11
213	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. <i>JCI Insight</i> , 2018, 3, .	5.0	86
214	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. <i>Diabetes</i> , 2018, 67, 145-OR.	0.6	3
215	Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis. <i>Diabetes</i> , 2018, 67, 147-OR.	0.6	1
216	Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption. <i>Diabetes</i> , 2018, 67, .	0.6	4

#	ARTICLE	IF	CITATIONS
217	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 Inhibition. Diabetes, 2018, 67, 1942-P.	0.6	2
218	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Dipeptidyl Peptidase-4 Inhibition. Diabetes, 2018, 67, .	0.6	3
219	The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals. Diabetes, 2018, 67, .	0.6	0
220	Clinical Features and Hepatic Molecular Characteristics in NAFLD and NASH Patients Compared to Normal Weight Healthy Individuals. Diabetes, 2018, 67, .	0.6	1
221	More Subjects Achieved Composite Reductions of =1% HbA1c, =5% Body Weight, and =5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7). Diabetes, 2018, 67, .	0.6	0
222	Glucagon-Like Peptide-1 Is a Significant Determinant of the Second-Meal Effect in Patients with Type 2 Diabetes. Diabetes, 2018, 67, 1963-P.	0.6	0
223	The Role of Glucagon-Like Peptide-1 for the Postprandial Effects of Metformin in Type 2 Diabetes. Diabetes, 2018, 67, .	0.6	0
224	Management of Patients with Type 2 Diabetes Shared between a Specialized Outpatient Clinic and General Practice Was Noninferior to Mono Management in a Specialized Outpatient Clinicâ€”A Prospective, Randomized, Noninferiority Trial. Diabetes, 2018, 67, .	0.6	3
225	Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opinion on Drug Safety, 2017, 16, 351-363.	2.4	30
226	Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liverâ€™s Î±-Cell Axis. Diabetes, 2017, 66, 235-240.	0.6	144
227	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Opinion on Drug Safety, 2017, 16, 387-396.	2.4	16
228	Glucagonâ€like peptideâ€1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 906-908.	4.4	90
229	Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opinion on Pharmacotherapy, 2017, 18, 555-571.	1.8	58
230	Shortâ€acting glucagonâ€like peptideâ€1 receptor agonists as addâ€on to insulin therapy in type 1 diabetes: <scp>A</scp> review. Diabetes, Obesity and Metabolism, 2017, 19, 915-925.	4.4	10
231	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. Journal of Diabetes and Its Complications, 2017, 31, 918-927.	2.3	72
232	No cognitiveâ€enhancing effect of <scp>GLP</scp>â€1 receptor agonism in antipsychoticâ€treated, obese patients with schizophrenia. Acta Psychiatrica Scandinavica, 2017, 136, 52-62.	4.5	36
233	Effect of exercise combined with glucagonâ€like peptideâ€1 receptor agonist treatment on cardiac function: <scp>A</scp> randomized doubleâ€blind placeboâ€controlled clinical trial. Diabetes, Obesity and Metabolism, 2017, 19, 1040-1044.	4.4	26
234	The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. BMJ Open, 2017, 7, e014728.	1.9	10



#	ARTICLE	IF	CITATIONS
235	Liraglutide â€” preventing or postponing T2DM diagnosis?. Nature Reviews Endocrinology, 2017, 13, 320-322.	9.6	1
236	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E284-E291.	3.5	13
237	The Gut: A Key to the Pathogenesis of Type 2 Diabetes?. Metabolic Syndrome and Related Disorders, 2017, 15, 259-262.	1.3	10
238	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. Diabetologia, 2017, 60, 1344-1353.	6.3	14
239	Mathematical Modelling of Glucoseâ€”Dependent Insulinotropic Polypeptide and Glucagonâ€”like Peptideâ€”1 following Ingestion of Glucose. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 290-297.	2.5	8
240	Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy Controls. Clinical Chemistry, 2017, 63, 1040-1041.	3.2	5
241	Evidence connecting old, new and neglected glucoseâ€”lowering drugs to bile acidâ€”induced <scp>GLP</scp>â€”1 secretion: <scp>A</scp> review. Diabetes, Obesity and Metabolism, 2017, 19, 1214-1222.	4.4	14
242	Incidence and Prognosis of Psoriasis and Psoriatic Arthritis in Patients Undergoing Bariatric Surgery. JAMA Surgery, 2017, 152, 344.	4.3	69
243	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics, 2017, 56, 719-731.	3.5	18
244	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 734-738.	4.4	16
245	Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?. Current Diabetes Reports, 2017, 17, 128.	4.2	18
246	Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 2017, 26, 611-619.e6.	16.2	689
247	Single-Dose Metformin Enhances Bile Acidâ€”Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4153-4162.	3.6	27
248	â€”No cognitiveâ€”enhancing effect of <scp>GLP</scp>â€”1 receptor agonism in antipsychoticâ€”treated, obese patients with schizophreniaâ€”TM: authors' response. Acta Psychiatrica Scandinavica, 2017, 136, 526-527.	4.5	0
249	OP0340â€”...Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal observational studies. , 2017, , .		1
250	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	6.4	28
251	Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1123-1129.	2.6	16
252	Adult atopic dermatitis and the risk of type 2 diabetes. Journal of Allergy and Clinical Immunology, 2017, 139, 1057-1059.	2.9	34



#	ARTICLE	IF	CITATIONS
253	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. <i>Diabetes Care</i> , 2017, 40, 109-116.	8.6	54
254	Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control study. <i>Diabetic Medicine</i> , 2017, 34, 272-277.	2.3	35
255	Effect of <scp>GLP</scp>-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: <scp>a</scp> randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 162-171.	4.4	53
256	The impact of <scp>EndoBarrier</scp> gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 189-199.	4.4	24
257	Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 172-180.	4.4	36
258	Clinical relevance of the bile acid receptor TGR5 in metabolism. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 224-233.	11.4	105
259	SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity. <i>Schizophrenia Bulletin</i> , 2017, 43, S167-S167.	4.3	2
260	Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 57.	2.7	56
261	MO019 INCRETIN EFFECT IS REDUCED IN END-STAGE RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii49-iii49.	0.7	0
262	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1870-1882.	0.9	98
263	Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 206-213.	8.6	62
264	Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-5.	2.3	33
265	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166125.	2.5	188
266	Effect of the <scp>EndoBarrier G</scp> gastrointestinal <scp>L</scp>iner on obesity and type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 300-305.	4.4	107
267	Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 955-961.	4.4	50
268	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 340-348.	2.0	14
269	Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 168-170.	2.5	35
270	Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 444-453.	4.4	62

#	ARTICLE	IF	CITATIONS
271	Diabetes and obesity treatment based on dual incretin receptor activation: â€˜twincretinsâ€™™. Diabetes, Obesity and Metabolism, 2016, 18, 847-854.	4.4	47
272	Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. Journal of Internal Medicine, 2016, 279, 485-493.	6.0	58
273	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine, 2016, 7, 112-120.	6.1	53
274	Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. Medical Hypotheses, 2016, 86, 100-103.	1.5	24
275	Vagotomy and subsequent development of diabetes â€˜ A nested caseâ€™control study. Metabolism: Clinical and Experimental, 2016, 65, 954-960.	3.4	6
276	The biology of glucagon and the consequences of hyperglucagonemia. Biomarkers in Medicine, 2016, 10, 1141-1151.	1.4	102
277	Speciesâ€™specific action of (Pro3)GIP â€™ a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 2016, 173, 27-38.	5.4	86
278	Nâ€™terminally and Câ€™terminally truncated forms of glucoseâ€™dependent insulinotropic polypeptide are highâ€™affinity competitive antagonists of the human GIP receptor. British Journal of Pharmacology, 2016, 173, 826-838.	5.4	72
279	Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: a randomised cross-over trial. Cardiovascular Diabetology, 2016, 15, 80.	6.8	71
280	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4377-4384.	3.6	12
281	Mechanismâ€™Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 692-700.	2.5	14
282	Effects of glucose-dependent insulinotropic polypeptide on glucagon. Cardiovascular Endocrinology, 2016, 5, 75-81.	0.8	1
283	Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasis. British Journal of Dermatology, 2016, 175, 1085-1088.	1.5	3
284	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2076-2083.	3.6	24
285	Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3002-3009.	3.6	100
286	Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study. BMC Health Services Research, 2016, 16, 124.	2.2	14
287	Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial. Trials, 2016, 17, 277.	1.6	7
288	Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagonâ€™like peptideâ€™1 secretion. Diabetes, Obesity and Metabolism, 2016, 18, 571-580.	4.4	71

#	ARTICLE	IF	CITATIONS
289	Evidence of Extrapaneatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.6	136
290	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, 2016, 4, 221-232.	11.4	127
291	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. Diabetes Care, 2016, 39, 617-624.	8.6	46
292	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. American Journal of Physiology - Renal Physiology, 2016, 310, G43-G51.	3.4	45
293	GLP-1 and Amylin in the Treatment of Obesity. Current Diabetes Reports, 2016, 16, 1.	4.2	56
294	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 908-915.	3.7	20
295	A comprehensive compartmental model of blood glucose regulation for healthy and type 2 diabetic subjects. Medical and Biological Engineering and Computing, 2016, 54, 1383-1398.	2.8	15
296	Retinal vascular and structural dynamics during acute hyperglycaemia. Acta Ophthalmologica, 2015, 93, 697-705.	1.1	11
297	Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. Journal of Internal Medicine, 2015, 278, 660-670.	6.0	22
298	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1522-1528.	2.8	15
299	Response to the Letter: "Epidemiologic Association Between Antibiotic Use With the Risk of Developing Type 2 Diabetes" by López-Hernández, D.. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L121-L121.	3.6	0
300	Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. PLoS ONE, 2015, 10, e0142352.	2.5	85
301	Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes, Obesity and Metabolism, 2015, 17, 546-553.	4.4	16
302	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open, 2015, 5, e007791-e007791.	1.9	12
303	Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858-1867. Diabetes Care, 2015, 38, e215-e215.	8.6	5
304	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R544-R551.	1.8	22
305	Patients with psoriasis are insulin resistant. Journal of the American Academy of Dermatology, 2015, 72, 599-605.	1.2	62
306	Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential. Diabetes, Obesity and Metabolism, 2015, 17, 116-120.	4.4	10

#	ARTICLE	IF	CITATIONS
307	Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients – a randomized placebo-controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 555-559.	2.4	39
308	Plasma YKL-40 during pregnancy and gestational diabetes mellitus. <i>Journal of Reproductive Immunology</i> , 2015, 112, 68-72.	1.9	6
309	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. <i>Peptides</i> , 2015, 71, 229-231.	2.4	15
310	Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. <i>Psychoneuroendocrinology</i> , 2015, 60, 1-6.	2.7	8
311	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 171-180.	2.4	24
312	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1493-1503.	3.3	13
313	Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 2254-2258.	6.3	94
314	Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. <i>Diabetes Care</i> , 2015, 38, e71-e72.	8.6	11
315	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. <i>European Journal of Endocrinology</i> , 2015, 173, 205-215.	3.7	11
316	Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 273-282.	3.1	1
317	Premature explantation of an EndoBarrier gastrointestinal liner because of sleeve invagination. <i>Endoscopy</i> , 2015, 47, E275-E276.	1.8	3
318	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4541-4552.	3.6	65
319	Use of Antibiotics and Risk of Type 2 Diabetes: A Population-Based Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3633-3640.	3.6	118
320	Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 513-520.	0.7	16
321	Recovery of the Incretin Effect in Type 2 Diabetic Patients After Biliopancreatic Diversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1984-1988.	3.6	9
322	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. <i>International Journal of Obesity</i> , 2015, 39, 1651-1654.	3.4	41
323	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 72-78.	0.6	60
324	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. <i>Clinical Investigation</i> , 2014, 4, 729-743.	0.0	3

#	ARTICLE	IF	CITATIONS
325	MECHANISMS IN ENDOCRINOLOGY: Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. <i>European Journal of Endocrinology</i> , 2014, 171, R47-R65.	3.7	62
326	A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease. <i>Case Reports in Gastroenterology</i> , 2014, 8, 398-403.	0.6	2
327	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2325-E2329.	3.6	104
328	The Authors Reply:. <i>Kidney International</i> , 2014, 85, 212-213.	5.2	0
329	The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1143-1149.	1.5	6
330	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. <i>Endocrine Connections</i> , 2014, 3, 193-199.	1.9	2
331	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonistâ€”protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. <i>BMJ Open</i> , 2014, 4, e004158.	1.9	20
332	The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. <i>European Journal of Endocrinology</i> , 2014, 171, 353-362.	3.7	25
333	Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. <i>BMJ Open</i> , 2014, 4, e005325.	1.9	52
334	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. <i>European Journal of Endocrinology</i> , 2014, 170, 529-538.	3.7	116
335	Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 670-676.	2.6	34
336	Poster #S8 GLUCOMETABOLIC HORMONES AND CARDIOVASCULAR RISK MARKERS IN ANTIPSYCHOTIC-TREATED PATIENTS. <i>Schizophrenia Research</i> , 2014, 153, S90-S91.	2.0	0
337	Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. <i>Acta Diabetologica</i> , 2014, 51, 147-150.	2.5	38
338	Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. <i>Acta Diabetologica</i> , 2014, 51, 567-575.	2.5	27
339	Use of exenatide and liraglutide in Denmark: a drug utilization study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 205-214.	1.9	10
340	Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2014, 14, 482.	4.2	43
341	Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young--Type 2 and Type 3. <i>Diabetes</i> , 2014, 63, 2838-2844.	0.6	43
342	Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E418-E426.	3.6	79

#	ARTICLE	IF	CITATIONS
343	Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. <i>Journal of Hepatology</i> , 2014, 60, 824-831.	3.7	475
344	Glucagon and Type 2 Diabetes: the Return of the Alpha Cell. <i>Current Diabetes Reports</i> , 2014, 14, 555.	4.2	96
345	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. <i>European Journal of Endocrinology</i> , 2014, 171, 407-419.	3.7	56
346	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 1223-1251.	5.0	23
347	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. <i>Diabetologia</i> , 2014, 57, 1720-1725.	6.3	56
348	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , 2014, 57, 1919-1926.	6.3	156
349	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. <i>BMC Research Notes</i> , 2014, 7, 326.	1.4	1
350	Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 119-127.	0.7	14
351	Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2457-2466.	3.6	31
352	Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1155-1164.	4.4	85
353	Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial. <i>Diabetes Care</i> , 2014, 37, 1797-1805.	8.6	94
354	Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 67, 69-76.	1.9	66
355	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. <i>European Journal of Internal Medicine</i> , 2014, 25, 407-414.	2.2	120
356	Decreased plasma chemerin levels in women with gestational diabetes mellitus. <i>Diabetic Medicine</i> , 2014, 31, 936-940.	2.3	24
357	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. <i>BMJ Open</i> , 2014, 4, e005378-e005378.	1.9	4
358	Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e899-e905.	2.2	19
359	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. <i>Diabetologia</i> , 2013, 56, 965-972.	6.3	199
360	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3346-3352.	8.6	125



#	ARTICLE	IF	CITATIONS
361	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies. <i>BMJ Open</i> , 2013, 3, e003417.	1.9	19
362	Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the <sc>TCF7L2</sc> rs7903146 risk T allele. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 91-95.	4.4	24
363	GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 17-29.	3.3	49
364	Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. <i>Regulatory Peptides</i> , 2013, 186, 104-107.	1.9	21
365	The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome. , 2013, , 165-183.		0
366	Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. <i>Diabetic Medicine</i> , 2013, 30, 1214-1218.	2.3	57
367	Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. <i>Kidney International</i> , 2013, 83, 915-923.	5.2	29
368	Reduced postprandial <sc>GLP</sc> responses in women with gestational diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 713-720.	4.4	37
369	Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. <i>BMJ Open</i> , 2013, 3, e002764.	1.9	11
370	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. <i>BMJ Open</i> , 2013, 3, e003834.	1.9	9
371	Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes. <i>American Journal of Psychiatry</i> , 2013, 170, 681-682.	7.2	21
372	Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G413-G419.	3.4	43
373	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G1117-G1127.	3.4	138
374	Mechanism of Metabolic Advantages After Bariatric Surgery. <i>Diabetes Care</i> , 2013, 36, S287-S291.	8.6	70
375	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. <i>European Journal of Endocrinology</i> , 2013, 169, 187-201.	3.7	51
376	Cardiovascular effects of alpha-linolenic acid – a possible role of glucagon-like peptide-1. <i>Experimental Biology and Medicine</i> , 2013, 238, 1116-1117.	2.4	0
377	Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. <i>Experimental Dermatology</i> , 2013, 22, 150-152.	2.9	25
378	TASK-1 potassium channel mutations in atrial fibrillation. <i>European Heart Journal</i> , 2013, 34, 3411-3411.	2.2	4



#	ARTICLE	IF	CITATIONS
379	Lixisenatide for the treatment of type 2 diabetes. <i>Drugs of Today</i> , 2013, 49, 537.	1.1	18
380	Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2013, 8, e73154.	2.5	38
381	Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2012, 2, e001803.	1.9	7
382	Comment on: Gogebakan et al. Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. <i>Diabetes</i> 2012;61:292-300. <i>Diabetes</i> , 2012, 61, e12-e12.	0.6	1
383	Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. <i>Current Medical Research and Opinion</i> , 2012, 28, 731-736.	1.9	13
384	Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1363-1370.	3.6	61
385	Add-on to metformin in T2DM—linagliptin or glimepiride?. <i>Nature Reviews Endocrinology</i> , 2012, 8, 576-578.	9.6	0
386	Letter by Knop Regarding Article, “Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial”. <i>Circulation</i> , 2012, 125, e428.	1.6	0
387	Increased Levels of YKL-40 and Interleukin 6 in Patients With Chronic Pancreatitis and Secondary Diabetes. <i>Pancreas</i> , 2012, 41, 1316-1318.	1.1	14
388	The unobtainable placebo: control of independent clinical research by industry?. <i>Lancet</i> , The, 2012, 379, 30.	13.7	12
389	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2012, 344, d7771-d7771.	2.3	731
390	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , 2012, 10, 92.	5.5	24
391	Authors' reply to de Oliveira and Iverson. <i>BMJ: British Medical Journal</i> , 2012, 344, e1459-e1459.	2.3	0
392	Glucagon and the gut hormones GLP-1 and oxyntomodulin increase resting energy expenditure in man. <i>Regulatory Peptides</i> , 2012, 177, S15-S16.	1.9	2
393	Acute dipeptidyl peptidase 4 inhibition has no impact on the incretin effect, glucose tolerance or gastric emptying in healthy subjects. <i>Regulatory Peptides</i> , 2012, 177, S30-S31.	1.9	0
394	Current evidence for a role of GLP-1 in Roux-Y gastric bypass-induced remission of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 291-298.	4.4	41
395	Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 500-510.	4.4	153
396	Electroretinography in healthy subjects in relation to systemic glucocorticoid intake. <i>Documenta Ophthalmologica</i> , 2012, 124, 49-57.	2.2	3

#	ARTICLE	IF	CITATIONS
397	GLP-1 Receptor Agonists and DPP-4 Inhibitors. MD Conference Express, 2012, 12, 24-26.	0.0	1
398	Emerging GLP-1 receptor agonists. Expert Opinion on Emerging Drugs, 2011, 16, 607-618.	2.4	21
399	2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1409-E1417.	3.6	238
400	Gastric bypass surgery: Improving psoriasis through a GLP-1-dependent mechanism?. Medical Hypotheses, 2011, 77, 1098-1101.	1.5	34
401	First Case Report Associating Chronic Pancreatitis and Ehlers-Danlos Syndrome. Pancreas, 2011, 40, 157-159.	1.1	1
402	Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 965-971.	4.4	114
403	Regulation of glucagon secretion by incretins. Diabetes, Obesity and Metabolism, 2011, 13, 89-94.	4.4	132
404	Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2011, 20, 549-557.	4.1	70
405	Gastric Emptying of Orally Administered Glucose Solutions and Incretin Hormone Responses Are Unaffected by Laparoscopic Adjustable Gastric Banding. Obesity Surgery, 2011, 21, 625-632.	2.1	31
406	Comment on: Chen et al. Utilizing the Second-Meal Effect in Type 2 Diabetes: Practical Use of a Soya-Yogurt Snack. Diabetes Care 2010;33:2552-2554. Diabetes Care, 2011, 34, e44-e44.	8.6	2
407	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology and Metabolism, 2011, 6, 513-525.	2.4	5
408	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. Diabetes Care, 2011, 34, S251-S257.	8.6	233
409	Increased Postprandial GIP and Glucagon Responses, But Unaltered GLP-1 Response after Intervention with Steroid Hormone, Relative Physical Inactivity, And High-Calorie Diet in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 447-453.	3.6	152
410	Glucose-Dependent Insulinotropic Polypeptide. Diabetes, 2011, 60, 3103-3109.	0.6	265
411	Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 737-745.	3.6	190
412	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E1038-E1046.	3.5	148
413	Therapy for Obesity Based on Gastrointestinal Hormones. Review of Diabetic Studies, 2011, 8, 339-347.	1.3	9
414	The Alpha-Cell as Target for Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 369-381.	1.3	49

#	ARTICLE	IF	CITATIONS
415	Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?. Current Diabetes Reports, 2010, 10, 124-132.	4.2	42
416	Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. Regulatory Peptides, 2010, 164, 144-150.	1.9	29
417	Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2010, 12, 323-333.	4.4	104
418	The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action. Diabetes, 2010, 59, 1765-1770.	0.6	230
419	Comment on: Villareal et al. (2009) TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action. Diabetes;59:479-485. Diabetes, 2010, 59, e4-e4.	0.6	3
420	Reduced Glucose Tolerance and Insulin Resistance Induced by Steroid Treatment, Relative Physical Inactivity, and High-Calorie Diet Impairs the Incretin Effect in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3309-3317.	3.6	92
421	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E832-E837.	3.5	67
422	Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E10-E13.	3.5	53
423	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2367-2375.	3.6	31
424	Increased Postprandial Response of Glucagon-Like Peptide-2 in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency. Pancreatology, 2010, 10, 201-207.	1.1	8
425	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides, 2010, 163, 96-101.	1.9	18
426	Incretin-Based Therapy and Type 2 Diabetes. Vitamins and Hormones, 2010, 84, 389-413.	1.7	20
427	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 155-63.	2.4	12
428	Incretin hormones and beta cell function in chronic pancreatitis. Danish Medical Bulletin, 2010, 57, B4163.	0.3	8
429	The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency. JOP: Journal of the Pancreas, 2010, 11, 489-91.	1.5	1
430	Incretin-Based Therapy of Type 2 Diabetes Mellitus. Current Protein and Peptide Science, 2009, 10, 46-55.	1.4	40
431	Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4679-4687.	3.6	89
432	K <sup>ATP</sup> Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 603-608.	3.6	48

#	ARTICLE	IF	CITATIONS
433	Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. <i>Diabetologia</i> , 2009, 52, 199-207.	6.3	351
434	Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?. <i>Diabetologia</i> , 2009, 52, 2270-2276.	6.3	77
435	Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. <i>International Journal of Clinical Practice</i> , 2009, 63, 1154-1160.	1.7	36
436	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 453-462.	4.7	21
437	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. <i>IDrugs: the Investigational Drugs Journal</i> , 2009, 12, 503-13.	0.7	26
438	Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. <i>Diabetologia</i> , 2008, 51, 632-640.	6.3	82
439	25th Scientific Meeting of the Anglo-Danish-Dutch Diabetes Group. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 17-17.	0.2	0
440	Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2008, 25, 1268-1275.	2.3	45
441	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq1 1 0.784314 rgB1/Over	1.0	14
442	Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus. <i>BioDrugs</i> , 2008, 22, 251-257.	4.6	19
443	Response to Comment on: Knop et al. (2007) Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? <i>Diabetes</i> 56:1951 1959. <i>Diabetes</i> , 2008, 57, e2-e3.	0.6	2
444	Positioning Glucagon-like-peptide- 1 - based Treatments within an Optimal Management Regimen for Type 2 Diabetes. <i>European Endocrinology</i> , 2008, 4, 44.	1.5	1
445	Glucagon-like Peptides and Insulin Sensitivity. , 2008, , 233-254.		0
446	Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. <i>IDrugs: the Investigational Drugs Journal</i> , 2008, 11, 497-501.	0.7	6
447	Review: DPP IV inhibitors - current evidence and future directions. <i>British Journal of Diabetes and Vascular Disease</i> , 2007, 7, 69-74.	0.6	12
448	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E324-E330.	3.5	92
449	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. <i>Regulatory Peptides</i> , 2007, 144, 123-130.	1.9	55
450	Reduced Incretin Effect in Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1951-1959.	0.6	297

#	ARTICLE	IF	CITATIONS
451	Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. <i>Diabetologia</i> , 2007, 50, 797-805.	6.3	165
452	The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7297-7302.	7.1	142
453	Self-Expanding Metal Stents for Colonic Obstruction: Experiences From 104 Procedures in a Single Center. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 444-450.	1.3	130
454	Delayed Ischemic Cecal Perforation Despite Optimal Decompression After Placement of a Self-Expanding Metal Stent: Report of a Case. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 1970-1973.	1.3	4
455	The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide—Regardless of Etiology and Phenotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4897-4903.	3.6	197
456	Small-Bowel Hemangiosarcoma and Capsule Endoscopy. <i>Endoscopy</i> , 2003, 35, 637-637.	1.8	14
457	No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis. <i>Diabetes Care</i> , 2003, 26, 2581-2587.	8.6	39
458	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 155-163.	2.4	34
459	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, , 155.	2.4	3
460	A gut feeling about glucagon. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
461	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. <i>Diabetes</i> , 0, , .	0.6	1